Novel monoclonal antibodies against mouse C3 interfering with complement activation: description of fine specificity and applications to various immunoassays.
about
Novel Abeta peptide immunogens modulate plaque pathology and inflammation in a murine model of Alzheimer's disease.Control of the collective migration of enteric neural crest cells by the Complement anaphylatoxin C3a and N-cadherinPericytes and immune cells contribute to complement activation in tubulointerstitial fibrosis.Combination of factor H mutation and properdin deficiency causes severe C3 glomerulonephritisComplement-mediated inhibition of neovascularization reveals a point of convergence between innate immunity and angiogenesis.Contribution of complement activation pathways to neuropathology differs among mouse models of Alzheimer's disease.Modulation of the antitumor immune response by complement.Imaging of activated complement using ultrasmall superparamagnetic iron oxide particles (USPIO)--conjugated vectors: an in vivo in utero non-invasive method to predict placental insufficiency and abnormal fetal brain development.Anti-amyloid therapy protects against retinal pigmented epithelium damage and vision loss in a model of age-related macular degeneration.Differential contributions of C3, C5, and decay-accelerating factor to ethanol-induced fatty liver in mice.C3-dependent mechanism of microglial priming relevant to multiple sclerosis.Classical Complement Pathway Activation in the Kidneys of Women With Preeclampsia.Complement and alcoholic liver disease: role of C1q in the pathogenesis of ethanol-induced liver injury in miceRegulation of Toll-like receptor-mediated inflammatory response by complement in vivo.Complement activation in acetaminophen-induced liver injury in mice.Activator-specific requirement of properdin in the initiation and amplification of the alternative pathway complement.Complement regulatory protein Crry deficiency contributes to the antigen specific recall response in experimental autoimmune myasthenia gravis.Deficiency of decay-accelerating factor and complement receptor 1-related gene/protein y on murine platelets leads to complement-dependent clearance by the macrophage phagocytic receptor CRIgAn early complement-dependent and TLR-4-independent phase in the pathogenesis of ethanol-induced liver injury in mice.Real-time label-free detection of complement activation products in human serum by white light reflectance spectroscopyThe Ribosomal Protein S19 Suppresses Antitumor Immune Responses via the Complement C5a Receptor 1.Evidence for non-traditional activation of complement factor C3 during murine liver regenerationComplement C3 and C4 expression in C1q sufficient and deficient mouse models of Alzheimer's disease.Deficiency of the complement regulatory protein CD59 accelerates the development of diabetes-induced atherosclerosis in mice.Changes in extracellular matrix cause RPE cells to make basal deposits and activate the alternative complement pathway.Complement Factor D protects mice from ethanol-induced inflammation and liver injury.
P2860
Q25256570-C39C29F7-A70C-4643-BF08-4C1CEB42EDE5Q27302883-F5CAC7B0-AF6C-4C48-8132-6111C856B7D7Q30275101-25100609-AF00-4BC0-A463-264E4969F01AQ30415634-B92CE649-B265-4CCD-8A4D-25446FFA315DQ34374022-B7E48926-295E-48BB-B53F-69D341EE1310Q34550347-EF3544A0-EBA0-4D76-A247-ECFCCE022F8EQ34838919-1ECBF0E4-5A55-4525-B320-8DB97A9CF19CQ34890710-7EC79CAE-209F-48EE-9FE4-4258DC5BC357Q35105102-69DE34A2-7D9D-41D6-96A6-9DEC63B73301Q35721145-C9078F39-A141-494C-AE23-94B4ED31EB2FQ35734866-C9AFEE12-52DB-44EA-9DF1-BD4A6D290A5FQ35738052-EA454772-1DF5-4BEE-A214-99C6A154C4C1Q35739330-5D2C687A-2F80-4341-8CF8-BCCBF72734EEQ35850677-8B3F16BD-7A65-4413-8234-AC032122FB70Q35913165-2B080ADB-4432-42CD-9063-33AD0857E1CBQ36384714-BD13680A-0E9E-4974-A508-46D1A4CC54F2Q36471905-31480774-80BD-46E4-A5BD-0BC37B2CD85BQ36835163-D89B23E8-1589-41DB-A7B1-65BC2627605DQ37151689-9BC43F18-F49A-4063-86E5-D3653525E81BQ37343678-FCC325B2-CA1A-4E8F-B05E-5A33C5E19174Q38715342-BAAEB036-29EC-45BC-907A-6756C22BD56AQ41766859-42636226-E69B-46EF-B7A0-25CA45512803Q43249892-8D6ACFC4-728D-4BA6-8AFA-6DAD106D2E46Q50227375-DE2F26DF-3653-4B36-AAAF-3C8AB2B9A738Q52429262-7C58F1C5-841D-4F5B-9175-BC39DDFECBCFQ52723165-B65475CD-DF8A-465D-8B2C-4E827F1F8606
P2860
Novel monoclonal antibodies against mouse C3 interfering with complement activation: description of fine specificity and applications to various immunoassays.
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年学术文章
@wuu
2004年学术文章
@zh-cn
2004年学术文章
@zh-hans
2004年学术文章
@zh-my
2004年学术文章
@zh-sg
2004年學術文章
@yue
2004年學術文章
@zh
2004年學術文章
@zh-hant
name
Novel monoclonal antibodies ag ...... tions to various immunoassays.
@en
Novel monoclonal antibodies ag ...... tions to various immunoassays.
@nl
type
label
Novel monoclonal antibodies ag ...... tions to various immunoassays.
@en
Novel monoclonal antibodies ag ...... tions to various immunoassays.
@nl
prefLabel
Novel monoclonal antibodies ag ...... tions to various immunoassays.
@en
Novel monoclonal antibodies ag ...... tions to various immunoassays.
@nl
P2093
P50
P1433
P1476
Novel monoclonal antibodies ag ...... tions to various immunoassays.
@en
P2093
Dimitrios Mastellos
Emelia Argyropoulos
Eszter Oláh
Glória László
Maciej Markiewski
Ruxandra Tudoran
P304
P356
10.1016/J.MOLIMM.2003.10.019
P577
2004-03-01T00:00:00Z